Riluzole 13C6

[13C6]-Riluzole is a chemical compound that is used in research and development for the treatment of neurological disorders. It is a stable isotope-labeled analogue of the drug Riluzole, which is commonly used to treat patients with amyotrophic lateral sclerosis (ALS). The compound contains six carbon atoms that are labeled with the stable isotope carbon-13, which allows for easier tracking and identification during experiments. It is commonly used in studies to determine the metabolism, pharmacokinetics, and distribution of Riluzole in the body. [13C6]-Riluzole is typically administered to laboratory animals, such as mice or rats, through oral or intravenous routes. The compound is then monitored in blood, urine, and tissue samples to determine its absorption, distribution, metabolism, and elimination in the body. Chemically, [13C6]-Riluzole is classified as a benzothiazole derivative, and is known to modulate the release of glutamate, a neurotransmitter involved in the communication between nerve cells. The drug has been shown to have neuroprotective effects, and is believed to slow the progression of ALS by reducing the amount of glutamate in the brain and spinal cord. In summary, [13C6]-Riluzole is a stable isotope-labeled analogue of Riluzole that is used in research to study the pharmacokinetics and pharmacodynamics of the drug in the body. Its stable isotope labeling allows for easier tracking and identification during experiments, and it is commonly used in studies to determine the metabolism, distribution, and elimination of Riluzole in the body.